Anti-BCMA antibody, pharmaceutical composition of same, and applications thereof
Provided in the present invention are an anti-BCMA antibody, a pharmaceutical composition of same, and applications thereof. The anti-BCMA antibody of the present invention or an antigen binding fragment of same and the pharmaceutical composition thereof are applicable in treating B cell-related diseases.
1 . An anti-B cell maturation antigen (anti-BCMA) antibody or an antigen-binding fragment thereof, wherein the anti-BCMA antibody comprises a variable heavy chain domain (VH) comprising a CDR1 (HCDR1) as set forth in SEQ ID NO:68, a CDR2 (HCDR2) as set forth in SEQ ID NO:69, and a CDR3 (HCDR3) as set forth in SEQ ID NO:70, and a variable light chain domain (VL) comprising a CDR1 (LCDR1) as set forth in SEQ ID NO:71, a CDR2 (LCDR2) as set forth in SEQ ID NO:72, and a CDR3 (LCDR3) as set forth in SEQ ID NO:73.
2 . The anti-BCMA antibody or the antigen-binding fragment thereof of claim 1 , wherein the anti-BCMA antibody is a chimeric antibody or a complete human antibody.
3 . The anti-BCMA antibody or the antigen-binding fragment thereof of claim 2 , wherein the anti-BCMA antibody is a complete human antibody.
4 . A pharmaceutical composition, wherein the pharmaceutical composition comprises the anti-BCMA antibody or the antigen-binding fragment thereof of claim 1 , and a pharmaceutically acceptable excipient or carrier.
5 . The anti-BCMA antibody or the antigen-binding fragment thereof of claim 1 , wherein the amino acid sequence of the VH of the anti-BCMA antibody is as set forth in SEQ ID NO: 66 and the amino acid sequence of the VL of the anti-BCMA antibody is as set forth in SEQ ID NO: 67.
6 . The anti-BCMA antibody or the antigen-binding fragment thereof of claim 1 , wherein the heavy chain constant region sequence of the BCMA antibody is set forth in SEQ ID NO: 106, and/or the light chain constant region sequence is set forth in SEQ ID NO: 107.